On February 18, 2010 the U.S. Food & Drug Administration issued new limits on popular prescription Asthma inhalers and required the manufacturers to include new warnings on the products labeling.
The affected inhalers belong to a class of long-acting inhaled medications called Long-Acting Beta-Agonists (LABAs). The inhalers included in the FDA warning are Serevent, Advair, Symbicort and Foradil.
These new warnings are based on FDA’s analyses of studies showing an increased risk of severe exacerbation of asthma symptoms, leading to hospitalizations in pediatric and adult patients as well as death in some patients using LABAs for the treatment of asthma.
Do I Have an Asthma Inhaler Lawsuit? If you or a loved one have used any of the affected asthma inhalers and subsequently suffered from a serious injury or unfortunate death, you should contact us immediately. You may be entitled to compensation for your injuries or loss and we can help.
What’s the problem?
According to the American Lung Association, Asthma affects about 23 million Americans. Millions of asthma sufferers use Serevent, Advair, Symbicort and Foradil inhalers to treat the symptoms associated with the chronic inflammatory lung disease.
These inhalers relax the muscles in bronchial passages, allowing more air to flow. They generally provide immediate relief to asthma sufferers but unfortunately, do not treat the underlying inflammation. This creates the risk of a life-threatening condition.
The new FDA warning is based on clinical trial data showing that use of the LABA inhalers carry an increased risk of aggravating asthma symptoms leading to hospitalization and, in some cases, death.